Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Hammond

Showing results (601-610 of 711) with videos related to

Pageof 72
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 17, 1998
A phase I and translational study of sequential administration of the topoisomerase I and II inhibitors topotecan and etoposideL A Hammond, J R Eckardt, R Ganapathi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 4, 2001
Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignanciesM Hidalgo, L L Siu, J Nemunaitis, et al.
Abdominal Imaging|August 17, 2014
Fluoroscopic findings post-peroral esophageal myotomyCarla Harmath, Jeanne Horowitz, Senta Berggruen, et al.
Oncoimmunology|November 21, 2015
A high density of tertiary lymphoid structure B cells in lung tumors is associated with increased CD4<sup>+</sup> T cell receptor repertoire clonalityWei Zhu, Claire Germain, Zheng Liu, et al.
Blood|December 10, 2020
MYC-induced human acute myeloid leukemia requires a continuing IL-3/GM-CSF costimulusElizabeth Bulaeva, Davide Pellacani, Naoto Nakamichi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 20, 2004
Phase I trial of a murine antibody to MUC1 in patients with metastatic cancer: evidence for the activation of humoral and cellular antitumor immunityJ S de Bono, S Y Rha, J Stephenson, et al.
Cancer Immunology Research|August 30, 2017
Concurrent PD-1 Blockade Negates the Effects of OX40 Agonist Antibody in Combination Immunotherapy through Inducing T-cell ApoptosisRajeev K Shrimali, Shamim Ahmad, Vivek Verma, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 30, 2000
DX-8951f, a hexacyclic camptothecin analog, on a daily-times-five schedule: a phase I and pharmacokinetic study in patients with advanced solid malignanciesE K Rowinsky, T R Johnson, C E Geyer, et al.
BMC Public Health|March 21, 2023
Community coalition efforts to prevent childhood obesity: two-year results of the Shape Up Under 5 studyChristina D Economos, Larissa Calancie, Ariella R Korn, et al.
Immunogenetics|June 6, 2018
Nomenclature for the KIR of non-human speciesJames Robinson, Lisbeth A Guethlein, Giuseppe Maccari, et al.
Pageof 72

Showing results (601-610 of 711) with videos related to

Sort By:
Pageof 72
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 17, 1998
A phase I and translational study of sequential administration of the topoisomerase I and II inhibitors topotecan and etoposideL A Hammond, J R Eckardt, R Ganapathi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 4, 2001
Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignanciesM Hidalgo, L L Siu, J Nemunaitis, et al.
Abdominal Imaging|August 17, 2014
Fluoroscopic findings post-peroral esophageal myotomyCarla Harmath, Jeanne Horowitz, Senta Berggruen, et al.
Oncoimmunology|November 21, 2015
A high density of tertiary lymphoid structure B cells in lung tumors is associated with increased CD4<sup>+</sup> T cell receptor repertoire clonalityWei Zhu, Claire Germain, Zheng Liu, et al.
Blood|December 10, 2020
MYC-induced human acute myeloid leukemia requires a continuing IL-3/GM-CSF costimulusElizabeth Bulaeva, Davide Pellacani, Naoto Nakamichi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 20, 2004
Phase I trial of a murine antibody to MUC1 in patients with metastatic cancer: evidence for the activation of humoral and cellular antitumor immunityJ S de Bono, S Y Rha, J Stephenson, et al.
Cancer Immunology Research|August 30, 2017
Concurrent PD-1 Blockade Negates the Effects of OX40 Agonist Antibody in Combination Immunotherapy through Inducing T-cell ApoptosisRajeev K Shrimali, Shamim Ahmad, Vivek Verma, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 30, 2000
DX-8951f, a hexacyclic camptothecin analog, on a daily-times-five schedule: a phase I and pharmacokinetic study in patients with advanced solid malignanciesE K Rowinsky, T R Johnson, C E Geyer, et al.
BMC Public Health|March 21, 2023
Community coalition efforts to prevent childhood obesity: two-year results of the Shape Up Under 5 studyChristina D Economos, Larissa Calancie, Ariella R Korn, et al.
Immunogenetics|June 6, 2018
Nomenclature for the KIR of non-human speciesJames Robinson, Lisbeth A Guethlein, Giuseppe Maccari, et al.
Pageof 72